相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activity of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed, genetically high risk chronic lymphocytic leukemia (CLL)
T. S. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition
Annette Hayden et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells
Wei Fu et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol
K. A. Blum et al.
LEUKEMIA (2011)
The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine
E. Walsby et al.
LEUKEMIA (2011)
Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription
Sonal M. Manohar et al.
LEUKEMIA RESEARCH (2011)
Requirement of TFIIH kinase subunit Mat1 for RNA Pol II C-terminal domain Ser5 phosphorylation, transcription and mRNA turnover
Katja Helenius et al.
NUCLEIC ACIDS RESEARCH (2011)
8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma
Jennifer B. Dennison et al.
BLOOD (2010)
A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels
Christine M. Stellrecht et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Responses in Mantle Cell Lymphoma Cells to SNS-032 Depend on the Biological Context of Each Cell Line
Rong Chen et al.
CANCER RESEARCH (2010)
RNA Polymerase II C-terminal Heptarepeat Domain Ser-7 Phosphorylation Is Established in a Mediator-dependent Fashion
Stefan Boeing et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Flavopiridol, Fludarabine, and Rituximab in Mantle Cell Lymphoma and Indolent B-Cell Lymphoproliferative Disorders
Thomas S. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
Wei-Gang Tong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
8-Amino-Adenosine Inhibits Multiple Mechanisms of Transcription
Jennifer Ann Frey et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
David Parry et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Nucleoside analog ARC targets Mcl-1 to induce apoptosis in leukemia cells
U. G. Bhat et al.
LEUKEMIA (2010)
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
L. Santo et al.
ONCOGENE (2010)
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
Kamil Paruch et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
Mitch A. Phelps et al.
BLOOD (2009)
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia
Rong Chen et al.
BLOOD (2009)
Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis
Jennifer B. Dennison et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Targeting MET transcription as a therapeutic strategy in multiple myeloma
Cornel J. Phillip et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
Andrew Conroy et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer
Wen-Son Hsieh et al.
CLINICAL CANCER RESEARCH (2009)
The basal initiation machinery: beyond the general transcription factors
Timothy W. Sikorski et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
The transcription elongation factors NELF, DSIF and P-TEFb control constitutive transcription in a gene-specific manner
Toshitsugu Fujita et al.
FEBS LETTERS (2009)
TFIIH-Associated Cdk7 Kinase Functions in Phosphorylation of C-Terminal Domain Ser7 Residues, Promoter-Proximal Pausing, and Termination by RNA Polymerase II
Kira Glover-Cutter et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
Matthew S. Squires et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Progression through the RNA Polymerase II CTD Cycle
Stephen Buratowski
MOLECULAR CELL (2009)
Shifting Players and Paradigms in Cell-Specific Transcription
Joseph A. D'Alessio et al.
MOLECULAR CELL (2009)
Phosphorylation of the RNA polymerase II C-terminal domain by TFIIH kinase is not essential for transcription of Saccharomyces cerevisiae genome
Sun Woo Hong et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells
Lisa S. Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Novel anticancer compounds induce apoptosis in melanoma cells
Uppoor G. Bhat et al.
CELL CYCLE (2008)
TFIID component TAF7 functionally interacts with both TFIIH and P-TEFb
Anne Gegonne et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology
Shudong Wang et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2008)
Differential sensitivity of human colon cancer cell lines to the nucleoside analogs ARC and DRB
Uppoor G. Bhat et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells
S. K. Radhakrishnan et al.
ONCOGENE (2008)
Protein factors in pre-mRNA 3'-end processing
C. R. Mandel et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
The cyclin-dependent kinase inhibitor seliciclib (Rroscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis
Steven R. Whittaker et al.
CELL CYCLE (2007)
Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection
D. Y. H. Hallaert et al.
CELL DEATH AND DIFFERENTIATION (2007)
Flavopiridol in the treatment of chronic lymphocytic leukemia
Beth A. Christian et al.
CURRENT OPINION IN ONCOLOGY (2007)
Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase
Christine M. Stellrecht et al.
CANCER RESEARCH (2007)
Phosphorylation of the c-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression
Yutaka Hirose et al.
JOURNAL OF BIOCHEMISTRY (2007)
Chemical inhibition of the TFIIH-associated kinase Cdk7/Kin28 does not impair global mRNA synthesis
Elenita I. Kanin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00
Kalpana S. Joshi et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Mechanism and functional role of XIAP and McI-1 down-regulation in flavopiridol/vorinostat antileukemic interactions
Roberto R. Rosato et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status
Eva Weingrill et al.
HAEMATOLOGICA (2007)
Free radical reactions might contribute to severe alpha amanitin hepatotoxicity - A hypothesis
Antoaneta Zheleva et al.
MEDICAL HYPOTHESES (2007)
Phosphorylation and functions of the RNA polymerase IICTD
Hemali P. Phatnani et al.
GENES & DEVELOPMENT (2006)
In vitro and in vivo activity of R547:: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials
Wanda DePinto et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells
Elliot B. Sambol et al.
CANCER RESEARCH (2006)
A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity.
SK Radhakrishnan et al.
CANCER RESEARCH (2006)
8-chloroadenosine induced HL-60 cell growth inhibition, differentiation, and G(0)/G(1) arrest involves attenuated cyclin D1 and telomerase and up-regulated p21(WAF1/CIP1)
B Zhu et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
Transcription inhibition: A potential strategy for cancer therapeutics
FA Derheimer et al.
EUROPEAN JOURNAL OF CANCER (2005)
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
R Chen et al.
BLOOD (2005)
Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine
K Balakrishnan et al.
CLINICAL CANCER RESEARCH (2005)
Roscovitine targets, protein kinases and pyridoxal kinase
S Bach et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
N Raje et al.
BLOOD (2005)
Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1
DE MacCallum et al.
CANCER RESEARCH (2005)
Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP
K Balakrishnan et al.
BLOOD (2005)
A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival
AJ Alvi et al.
BLOOD (2005)
8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: Role in induction of apoptosis in multiple myeloma
K Ghias et al.
MOLECULAR CANCER THERAPEUTICS (2005)
N-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase -: 2.: N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent
RN Misra et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Coordination of transcription, RNA processing, and surveillance by P-TEFb kinase on heat shock genes
ZY Ni et al.
MOLECULAR CELL (2004)
Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP
EH Kim et al.
ONCOGENE (2004)
Chain termination and inhibition of Saccharomyces cerevisiae poly(A) polymerase by C-8-modified ATP analogs
LS Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol
GI Shapiro
CLINICAL CANCER RESEARCH (2004)
Exposure of human lung cancer cells to 8-chloro-adenosine induces G2/M arrest and mitotic catastrophe
HY Zhang et al.
NEOPLASIA (2004)
Clinical and cellular pharmacology in relation to solid tumours of childhood
EJ Estlin et al.
CANCER TREATMENT REVIEWS (2003)
ARED 2.0: an update of AU-rich element mRNA database
T Bakheet et al.
NUCLEIC ACIDS RESEARCH (2003)
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)
SJ McClue et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats
V Gandhi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Developmental Therapeutics Program at the NCI: molecular target and drug discovery process
M Monga et al.
LEUKEMIA (2002)
Structural basis of transcription:: α-Amanitin-RNA polymerase II cocrystal at 2.8 A resolution
DA Bushnell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol
I Semenov et al.
LEUKEMIA RESEARCH (2002)
Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo
SH Chao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors
D Wang et al.
JOURNAL OF VIROLOGY (2001)
Mechanisms of action of flavopiridol
HH Sedlacek
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2001)
The cap-to-tail guide to mRNA turnover
CJ Wilusz et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication
SH Chao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
8-Cl-adenosine-induced inhibition of colorectal cancer growth in vitro and in vivo
CC Carlson et al.
NEOPLASIA (2000)
Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine
P Huang et al.
LEUKEMIA (2000)
分享论文
